Australia's Genetic Signatures jumps on US FDA nod for diagnosis kit
** Shares of molecular diagnostics firm Genetic Signatures
GSS.AX rise as much as 16.4% to A$0.850, their highest since
mid-Feb 2023
** Stock posts its biggest intraday pct gain since March 4
** Co said on Wednesday the U.S. Food and Drug
Administration cleared its 'EasyScreen' gastrointestinal
parasite detection kit in the U.S.
** Over 1 mln shares change hands, compared with the 30-day
average volume of around 120,000
** Stock up 67.8% YTD, based on last close
(Reporting by Aaditya Govind Rao in Bengaluru)
((Aaditya.govindrao@thomsonreuters.com;))
Recent news on Genetic Signatures
See all newsBrief: Genetic Signatures Says Microba Shareholders To Hold 60% Of GSS On Merger
Australia's Genetic Signatures urges largest stakeholder to clarify merger intentions; shares rise
Brief: Genetic Signatures Receives Request From BCAL Diagnostics To Call General Meeting Of Shareholders
Brief: Genetic Signatures Requested BCAL Diagnostics To Clarify Details Of Shareholdings, Associates In Co
Brief: Genetic Signatures Announces Board Changes